{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:50:34Z","timestamp":1791449434266,"version":"4.3.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Japan Agency for Medical Research","award":["24ck0106978h0001"],"award-info":[{"award-number":["24ck0106978h0001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01898-5","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:10:21Z","timestamp":1787904621000},"page":"5085-5097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic Medium-Class Topical Steroids are Associated with a Lower Incidence of Capecitabine-Induced Hand-Foot Syndrome in Patients with Colorectal Cancer"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3473-8244","authenticated-orcid":false,"given":"Yohei","family":"Iimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Ahiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Monma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sakuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Aikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Shida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"1898_CR1","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","volume":"16","author":"V Sibaud","year":"2011","unstructured":"Sibaud V, Dalenc F, Chevreau C, Roch\u00e9 H, Delord JP, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist. 2011;16:1469\u201378. https:\/\/doi.org\/10.1634\/theoncologist.2011-0033.","journal-title":"Oncologist"},{"key":"1898_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378:1177\u201388. https:\/\/doi.org\/10.1056\/NEJMoa1713709.","journal-title":"N Engl J Med"},{"key":"1898_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2020.10.480","volume":"32","author":"K Yamazaki","year":"2021","unstructured":"Yamazaki K, Yamanaka T, Shiozawa M, Manaka D, Kotaka M, Gamoh M, et al. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial. Ann Oncol. 2021;32:77\u201384. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.480.","journal-title":"Ann Oncol"},{"key":"1898_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2468-1253(17)30297-2","volume":"3","author":"T Hamaguchi","year":"2018","unstructured":"Hamaguchi T, Shimada Y, Mizusawa J, Kinugasa Y, Kanemitsu Y, Ohue M, et al. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3:47\u201356. https:\/\/doi.org\/10.1016\/S2468-1253(17)30297-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1898_CR5","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1177\/1060028015594451","volume":"49","author":"T Yokokawa","year":"2015","unstructured":"Yokokawa T, Kawakami K, Mae Y, Sugita K, Watanabe H, Suzuki K, et al. Risk factors exacerbating hand-foot skin reaction induced by capecitabine plus oxaliplatin with or without bevacizumab therapy. Ann Pharmacother. 2015;49:1120\u20134. https:\/\/doi.org\/10.1177\/1060028015594451.","journal-title":"Ann Pharmacother"},{"key":"1898_CR6","unstructured":"National Comprehensive Cancer Network (2026) NCCN Guidelines. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1428. Accessed May 15, 2026."},{"key":"1898_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/PPA.S80327","volume":"9","author":"K Kawakami","year":"2015","unstructured":"Kawakami K, Nakamoto E, Yokokawa T, Sugita K, Mae Y, Hagino A, et al. Patients\u2019 self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis. Patient Prefer Adherence. 2015;9:561\u20137. https:\/\/doi.org\/10.2147\/PPA.S80327.","journal-title":"Patient Prefer Adherence"},{"key":"1898_CR8","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.3390\/curroncol28050342","volume":"28","author":"S Lakkunarajah","year":"2021","unstructured":"Lakkunarajah S, Breadner DA, Zhang H, Yamanaka E, Warner A, Welch S. The influence of adjuvant chemotherapy dose intensity on five-year outcomes in resected colon cancer: a single centre retrospective analysis. Curr Oncol. 2021;28:4031\u201341. https:\/\/doi.org\/10.3390\/curroncol28050342.","journal-title":"Curr Oncol"},{"key":"1898_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1610-0387.2010.07449.x","volume":"8","author":"A Degen","year":"2010","unstructured":"Degen A, Alter M, Schenck F, Satzger I, V\u00f6lker B, Kapp A, et al. The hand-foot-syndrome associated with medical tumor therapy\u2014classification and management. JDDG. 2010;8:652\u201361. https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07449.x.","journal-title":"JDDG"},{"key":"1898_CR10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3349\/ymj.2009.50.6.796","volume":"50","author":"HS Son","year":"2009","unstructured":"Son HS, Lee WY, Lee WS, Yun SH, Chun HK. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J. 2009;50:796\u2013802. https:\/\/doi.org\/10.3349\/ymj.2009.50.6.796.","journal-title":"Yonsei Med J"},{"key":"1898_CR11","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Van Cutsem","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097\u2013106. https:\/\/doi.org\/10.1200\/JCO.2001.19.21.4097.","journal-title":"J Clin Oncol"},{"key":"1898_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","volume":"17","author":"JL Blum","year":"1999","unstructured":"Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485\u201393. https:\/\/doi.org\/10.1200\/JCO.1999.17.2.485.","journal-title":"J Clin Oncol"},{"key":"1898_CR13","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.21037\/apm-21-61","volume":"10","author":"W Lu","year":"2021","unstructured":"Lu W, Huang Z, Chen S, Lv H, Chen X, Lei J, et al. The effectiveness of EVOSKIN\u00aePalm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial. Ann Palliat Med. 2021;10:3009\u201317. https:\/\/doi.org\/10.21037\/apm-21-61.","journal-title":"Ann Palliat Med"},{"key":"1898_CR14","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1200\/JCO.2010.31.1431","volume":"28","author":"SL Wolf","year":"2010","unstructured":"Wolf SL, Qin R, Menon SP, Rowland KM Jr, Thomas S, Delaune R, et al. Placebo-controlled trial to determine the effectiveness of a urea\/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol. 2010;28:5182\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.31.1431.","journal-title":"J Clin Oncol"},{"key":"1898_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00432-010-0958-9","volume":"137","author":"RX Zhang","year":"2011","unstructured":"Zhang RX, Wu XJ, Lu SX, Pan ZZ, Wan DS, Chen G. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II\/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol. 2011;137:953\u20137. https:\/\/doi.org\/10.1007\/s00432-010-0958-9.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1898_CR16","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/annonc\/mdr400","volume":"23","author":"RX Zhang","year":"2012","unstructured":"Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, et al. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 2012;23:1348\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdr400.","journal-title":"Ann Oncol"},{"key":"1898_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ced.12538","volume":"40","author":"SJ Jo","year":"2015","unstructured":"Jo SJ, Shin H, Jo S, Kwon O, Myung SK. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis. Clin Exp Dermatol. 2015;40:260\u201370. https:\/\/doi.org\/10.1111\/ced.12538.","journal-title":"Clin Exp Dermatol"},{"key":"1898_CR18","first-page":"1161","volume":"18","author":"W Scheithauer","year":"2004","unstructured":"Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park). 2004;18:1161\u20138.","journal-title":"Oncology (Williston Park)"},{"key":"1898_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","volume":"26","author":"N Yokomichi","year":"2013","unstructured":"Yokomichi N, Nagasawa T, Coler-Reilly A, Suzuki H, Kubota Y, Yoshioka R, et al. Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin. Hum Cell. 2013;26:8\u201318. https:\/\/doi.org\/10.1007\/s13577-012-0057-0.","journal-title":"Hum Cell"},{"key":"1898_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ygyno.2004.05.027","volume":"94","author":"RD Drake","year":"2004","unstructured":"Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol. 2004;94:320\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2004.05.027.","journal-title":"Gynecol Oncol"},{"key":"1898_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s0190-9622(08)80126-0","volume":"24","author":"J Brown","year":"1991","unstructured":"Brown J, Burck K, Black D, Collins C. Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol. 1991;24:1023\u20135. https:\/\/doi.org\/10.1016\/s0190-9622(08)80126-0.","journal-title":"J Am Acad Dermatol"},{"key":"1898_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/(sici)1097-0142(19980301)82:5<965::aid-cncr23>3.0.co;2-y","volume":"82","author":"PM Hoff","year":"1998","unstructured":"Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998;82:965\u20139. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19980301)82:5%3c965::aid-cncr23%3e3.0.co;2-y.","journal-title":"Cancer"},{"key":"1898_CR23","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","volume":"147","author":"R Van Doorn","year":"2002","unstructured":"Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147:598\u2013601. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04864.x.","journal-title":"Br J Dermatol"},{"key":"1898_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","volume":"144","author":"KJ Busam","year":"2001","unstructured":"Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144:1169\u201376. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04226.x.","journal-title":"Br J Dermatol"},{"key":"1898_CR25","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/j.1365-2133.2005.06885.x","volume":"153","author":"JC Pascual","year":"2005","unstructured":"Pascual JC, Belinch\u00f3n I, Sivera F, Yuste A. Severe cutaneous toxicity following treatment with gefitinib (ZD1839). Br J Dermatol. 2005;153:1222\u20133. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06885.x.","journal-title":"Br J Dermatol"},{"key":"1898_CR26","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351\u20137. https:\/\/doi.org\/10.1200\/JCO.2008.21.7828.","journal-title":"J Clin Oncol"},{"key":"1898_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/fon.14.251","volume":"11","author":"Y Kobayashi","year":"2015","unstructured":"Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol. 2015;11:617\u201327. https:\/\/doi.org\/10.2217\/fon.14.251.","journal-title":"Future Oncol"},{"key":"1898_CR28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.alit.2020.02.006","volume":"69","author":"N Katoh","year":"2020","unstructured":"Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020;69:356\u201369. https:\/\/doi.org\/10.1016\/j.alit.2020.02.006.","journal-title":"Allergol Int"},{"key":"1898_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"1898_CR30","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1200\/JCO.2014.60.4587","volume":"33","author":"RD Hofheinz","year":"2015","unstructured":"Hofheinz RD, Gencer D, Schulz H, Stahl M, Hegewisch-Becker S, Loeffler LM, et al. Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO quality of life working group. J Clin Oncol. 2015;33:2444\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.60.4587.","journal-title":"J Clin Oncol"},{"key":"1898_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086. https:\/\/doi.org\/10.1136\/bmj.c7086.","journal-title":"BMJ"},{"key":"1898_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4857","volume":"354","author":"A Arf\u00e8","year":"2016","unstructured":"Arf\u00e8 A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;354:i4857. https:\/\/doi.org\/10.1136\/bmj.i4857.","journal-title":"BMJ"},{"key":"1898_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1743-7563.2010.01311.x","volume":"6","author":"T Chalermchai","year":"2010","unstructured":"Chalermchai T, Tantiphlachiva K, Suwanrusme H, Voravud N, Sriuranpong V. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. Asia Pac J Clin Oncol. 2010;6:155\u201360. https:\/\/doi.org\/10.1111\/j.1743-7563.2010.01311.x.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1898_CR34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12282-009-0171-3","volume":"17","author":"N Yoshimoto","year":"2010","unstructured":"Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, et al. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer (Auckl). 2010;17:298\u2013302. https:\/\/doi.org\/10.1007\/s12282-009-0171-3.","journal-title":"Breast Cancer (Auckl)"},{"key":"1898_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/ced.14486","volume":"46","author":"S Lian","year":"2021","unstructured":"Lian S, Zhang X, Zhang Y, Zhao Q. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis. Clin Exp Dermatol. 2021;46:629\u201335. https:\/\/doi.org\/10.1111\/ced.14486.","journal-title":"Clin Exp Dermatol"},{"key":"1898_CR36","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3892\/br.2013.161","volume":"1","author":"Y Zhou","year":"2013","unstructured":"Zhou Y, Peng L, Li Y, Chen L. Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: a meta-analysis. Biomed Rep. 2013;1:873\u20138. https:\/\/doi.org\/10.3892\/br.2013.161.","journal-title":"Biomed Rep"},{"key":"1898_CR37","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1200\/JCO.2010.29.1807","volume":"28","author":"YK Kang","year":"2010","unstructured":"Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010;28:3824\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.29.1807.","journal-title":"J Clin Oncol"},{"key":"1898_CR38","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1001\/jamaoncol.2017.1269","volume":"3","author":"YS Yap","year":"2017","unstructured":"Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, et al. Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial. JAMA Oncol. 2017;3:1538\u201345. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1269.","journal-title":"JAMA Oncol"},{"key":"1898_CR39","doi-asserted-by":"publisher","first-page":"e1886","DOI":"10.1634\/theoncologist.2020-0698","volume":"25","author":"V Ostwal","year":"2020","unstructured":"Ostwal V, Kapoor A, Mandavkar S, Chavan N, Gupta T, Mirani J, et al. Effect of a structured teaching module including intensive prophylactic measures on reducing the incidence of capecitabine-induced hand-foot syndrome: results of a prospective randomized phase III study. Oncologist. 2020;25:e1886\u201392. https:\/\/doi.org\/10.1634\/theoncologist.2020-0698.","journal-title":"Oncologist"},{"key":"1898_CR40","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/JCO.23.01730","volume":"42","author":"A Santhosh","year":"2024","unstructured":"Santhosh A, Sharma A, Bakhshi S, Kumar A, Sharma V, Malik PS, et al. Topical diclofenac for prevention of capecitabine-associated hand-foot syndrome: a double-blind randomized controlled trial. J Clin Oncol. 2024;42:1821\u20139. https:\/\/doi.org\/10.1200\/JCO.23.01730.","journal-title":"J Clin Oncol"},{"key":"1898_CR41","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s10147-025-02789-z","volume":"30","author":"Y Iimura","year":"2025","unstructured":"Iimura Y, Ishiguro H, Hashimoto H, Nojima M, Oyamada S, Mori K, et al. A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401\/JORTC-SUP06 (J-DIRECT). Int J Clin Oncol. 2025;30:1553\u201361. https:\/\/doi.org\/10.1007\/s10147-025-02789-z.","journal-title":"Int J Clin Oncol"},{"key":"1898_CR42","first-page":"587","volume":"43","author":"K Okada","year":"2016","unstructured":"Okada K, Sadahiro S, Saito G, Tanaka A, Suzuki T. Postoperative adjuvant chemotherapy for stage III colon cancer\u2014drug selection, tolerability, and safety in clinical practice. Gan To Kagaku Ryoho. 2016;43:587\u201392.","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01898-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01898-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01898-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:31Z","timestamp":1791446431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01898-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01898-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yohei Iimura, Yuka Ahiko, Satoko Monma, Naoki Sakuyama, Susumu Aikou, Dai Shida, and Seiichiro Kuroda have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the data were anonymous, the requirement for informed consent was waived. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board of The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo (approval number: 2025\u201331-0918).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}